Class II FDA-cleared connected diabetes platform. Offshore team of 10+. Two months saved with a KMM proof-of-concept.
Eli Lilly's 2021 diabetes-product revenue totaled ~$9.6B (the engagement period). The Tempo connected-diabetes platform sits within Lilly's diabetes business — the figure is the client's scale as context, not a personal attribution. (Lilly FY2021 results, Feb 3 2022.)
Eli Lilly